David Amsellem Stock Analyst Profile - Piper Sandler Research Coverage - Stocknear

David Amsellem

Stock Analyst at Piper Sandler

(4.9)
# 687
Out of 5,506 analysts
196
Total ratings
Success rate
Average return

45 Stocks

Name Action PT Current % Upside Ratings Updated
SUPN Supernus Pharmaceuti...
Maintains: Neutral
36 40
48.35 -17.27% 13 Aug 29, 2025
AMGN Amgen
Maintains: Overweight
328 342
297.89 14.81% 5 Aug 25, 2025
BIIB Biogen
Maintains: Neutral
115 118
159.88 -26.19% 2 Aug 14, 2025
ABBV AbbVie
Assumes: Overweight
231
233.87 -1.23% 1 Aug 12, 2025
AMPH Amphastar Pharma
Maintains: Neutral
30 25
26.75 -6.54% 8 Aug 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
131 121
88.15 37.27% 8 Aug 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
154 175
137.03 27.71% 10 Jul 31, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
9 9
n/a n/a 2 Jun 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 18
11 63.64% 6 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
36 37
34.61 6.91% 8 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
176 147
139.48 5.39% 11 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
65
45.44 43.05% 1 Apr 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
15 9
n/a n/a 3 Mar 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
3 4
8.2 -51.22% 5 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
16 13
23.17 -43.89% 5 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
14 10
10.19 -1.86% 7 Mar 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
23 30
20 50% 10 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
107 132
n/a n/a 1 Jan 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 13
15.01 -13.39% 5 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
10.39 5.87% 4 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
38 37
31.06 19.12% 7 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
68
89.64 -24.14% 1 Oct 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
11 6
n/a n/a 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
9 3
6.68 -55.09% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
42 42
24.84 69.08% 7 Jul 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
10
5.8 72.41% 1 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 21
1.55 1254.84% 3 Feb 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 113
120.3 -6.07% 3 Jan 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
33 45
n/a n/a 2 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
432 36
n/a n/a 3 Nov 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
72 42
27.28 53.96% 3 Oct 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
26 17
n/a n/a 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
285
n/a n/a 1 Jan 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 110
n/a n/a 5 Dec 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3750 250
n/a n/a 2 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
6 6
n/a n/a 2 Apr 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
5 3
n/a n/a 5 Mar 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
5 6
n/a n/a 2 Feb 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 8
n/a n/a 1 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
23 17
n/a n/a 1 Apr 15, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
9
n/a n/a 4 Oct 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Mar 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 2 Jul 18, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 5 May 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
12
n/a n/a 1 Dec 19, 2016